nodes	percent_of_prediction	percent_of_DWPC	metapath
Agomelatine—CYP1A2—Anagrelide—hematologic cancer	0.0716	0.127	CbGbCtD
Agomelatine—CYP2C9—Bexarotene—hematologic cancer	0.0447	0.0794	CbGbCtD
Agomelatine—CYP1A2—Carmustine—hematologic cancer	0.0376	0.0667	CbGbCtD
Agomelatine—CYP2C9—Idarubicin—hematologic cancer	0.037	0.0658	CbGbCtD
Agomelatine—CYP1A2—Methoxsalen—hematologic cancer	0.032	0.0567	CbGbCtD
Agomelatine—CYP1A2—Bortezomib—hematologic cancer	0.0304	0.054	CbGbCtD
Agomelatine—CYP1A2—Daunorubicin—hematologic cancer	0.0291	0.0516	CbGbCtD
Agomelatine—CYP1A2—Alitretinoin—hematologic cancer	0.0285	0.0506	CbGbCtD
Agomelatine—CYP2C9—Bortezomib—hematologic cancer	0.0274	0.0486	CbGbCtD
Agomelatine—CYP1A2—Thalidomide—hematologic cancer	0.0265	0.047	CbGbCtD
Agomelatine—CYP2C9—Thalidomide—hematologic cancer	0.0239	0.0424	CbGbCtD
Agomelatine—CYP1A2—Dacarbazine—hematologic cancer	0.0228	0.0404	CbGbCtD
Agomelatine—CYP2C9—Teniposide—hematologic cancer	0.0228	0.0404	CbGbCtD
Agomelatine—CYP1A2—Imatinib—hematologic cancer	0.0223	0.0395	CbGbCtD
Agomelatine—CYP2C9—Ifosfamide—hematologic cancer	0.021	0.0373	CbGbCtD
Agomelatine—CYP2C9—Imatinib—hematologic cancer	0.0201	0.0356	CbGbCtD
Agomelatine—CYP2C9—Nilotinib—hematologic cancer	0.0182	0.0324	CbGbCtD
Agomelatine—CYP1A2—Dasatinib—hematologic cancer	0.0179	0.0318	CbGbCtD
Agomelatine—CYP1A2—Etoposide—hematologic cancer	0.0111	0.0198	CbGbCtD
Agomelatine—CYP2C9—Cisplatin—hematologic cancer	0.0102	0.0181	CbGbCtD
Agomelatine—CYP2C9—Dexamethasone—hematologic cancer	0.00826	0.0147	CbGbCtD
Agomelatine—MTNR1A—hematopoietic system—hematologic cancer	0.00593	0.314	CbGeAlD
Agomelatine—MTNR1A—blood—hematologic cancer	0.00393	0.208	CbGeAlD
Agomelatine—MTNR1A—testis—hematologic cancer	0.00325	0.172	CbGeAlD
Agomelatine—Melatonin—CALR—hematologic cancer	0.00226	0.346	CrCbGaD
Agomelatine—Nabumetone—MPO—hematologic cancer	0.00111	0.171	CrCbGaD
Agomelatine—CYP1A2—hematopoietic system—hematologic cancer	0.000931	0.0493	CbGeAlD
Agomelatine—HTR2B—blood—hematologic cancer	0.000903	0.0478	CbGeAlD
Agomelatine—CYP2C9—hematopoietic system—hematologic cancer	0.000884	0.0468	CbGeAlD
Agomelatine—HTR2B—lung—hematologic cancer	0.000792	0.0419	CbGeAlD
Agomelatine—Naproxen—UGT1A1—hematologic cancer	0.000702	0.108	CrCbGaD
Agomelatine—Indomethacin—ABCC3—hematologic cancer	0.000659	0.101	CrCbGaD
Agomelatine—CYP1A2—blood—hematologic cancer	0.000617	0.0326	CbGeAlD
Agomelatine—CYP2C9—blood—hematologic cancer	0.000585	0.031	CbGeAlD
Agomelatine—Indomethacin—UGT1A1—hematologic cancer	0.000569	0.0872	CrCbGaD
Agomelatine—HTR2B—lymph node—hematologic cancer	0.000541	0.0287	CbGeAlD
Agomelatine—CYP1A2—lung—hematologic cancer	0.000541	0.0286	CbGeAlD
Agomelatine—Melatonin—MPO—hematologic cancer	0.000444	0.068	CrCbGaD
Agomelatine—Melatonin—ESR1—hematologic cancer	0.000333	0.051	CrCbGaD
Agomelatine—Naproxen—ALB—hematologic cancer	0.000172	0.0264	CrCbGaD
Agomelatine—Indomethacin—ALB—hematologic cancer	0.00014	0.0214	CrCbGaD
Agomelatine—Indomethacin—ABCB1—hematologic cancer	0.000133	0.0204	CrCbGaD
Agomelatine—Somnolence—Etoposide—hematologic cancer	0.000106	0.000379	CcSEcCtD
Agomelatine—Hepatobiliary disease—Methotrexate—hematologic cancer	0.000106	0.000379	CcSEcCtD
Agomelatine—Nausea—Bortezomib—hematologic cancer	0.000106	0.000379	CcSEcCtD
Agomelatine—Asthenia—Vincristine—hematologic cancer	0.000106	0.000378	CcSEcCtD
Agomelatine—Paraesthesia—Prednisolone—hematologic cancer	0.000106	0.000378	CcSEcCtD
Agomelatine—Vomiting—Thiotepa—hematologic cancer	0.000106	0.000378	CcSEcCtD
Agomelatine—Diarrhoea—Carmustine—hematologic cancer	0.000106	0.000378	CcSEcCtD
Agomelatine—Mental disorder—Prednisone—hematologic cancer	0.000106	0.000377	CcSEcCtD
Agomelatine—Nausea—Bleomycin—hematologic cancer	0.000105	0.000376	CcSEcCtD
Agomelatine—Infestation—Epirubicin—hematologic cancer	0.000105	0.000375	CcSEcCtD
Agomelatine—Infestation NOS—Epirubicin—hematologic cancer	0.000105	0.000375	CcSEcCtD
Agomelatine—Hyperhidrosis—Triamcinolone—hematologic cancer	0.000105	0.000374	CcSEcCtD
Agomelatine—Diarrhoea—Alitretinoin—hematologic cancer	0.000105	0.000374	CcSEcCtD
Agomelatine—Headache—Thiotepa—hematologic cancer	0.000104	0.000372	CcSEcCtD
Agomelatine—Diarrhoea—Ifosfamide—hematologic cancer	0.000104	0.00037	CcSEcCtD
Agomelatine—Nausea—Vinorelbine—hematologic cancer	0.000104	0.00037	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Etoposide—hematologic cancer	0.000103	0.000369	CcSEcCtD
Agomelatine—Asthenia—Mitoxantrone—hematologic cancer	0.000103	0.000368	CcSEcCtD
Agomelatine—Asthenia—Irinotecan—hematologic cancer	0.000103	0.000368	CcSEcCtD
Agomelatine—Fatigue—Etoposide—hematologic cancer	0.000103	0.000368	CcSEcCtD
Agomelatine—Jaundice—Epirubicin—hematologic cancer	0.000102	0.000366	CcSEcCtD
Agomelatine—Vomiting—Thalidomide—hematologic cancer	0.000102	0.000365	CcSEcCtD
Agomelatine—Anxiety—Betamethasone—hematologic cancer	0.000102	0.000365	CcSEcCtD
Agomelatine—Anxiety—Dexamethasone—hematologic cancer	0.000102	0.000365	CcSEcCtD
Agomelatine—Dizziness—Carmustine—hematologic cancer	0.000102	0.000365	CcSEcCtD
Agomelatine—Constipation—Etoposide—hematologic cancer	0.000102	0.000365	CcSEcCtD
Agomelatine—Dizziness—Alitretinoin—hematologic cancer	0.000101	0.000362	CcSEcCtD
Agomelatine—Diarrhoea—Vincristine—hematologic cancer	0.000101	0.000361	CcSEcCtD
Agomelatine—Headache—Thalidomide—hematologic cancer	0.000101	0.00036	CcSEcCtD
Agomelatine—Hepatitis—Methotrexate—hematologic cancer	0.000101	0.00036	CcSEcCtD
Agomelatine—Asthenia—Gemcitabine—hematologic cancer	0.0001	0.000359	CcSEcCtD
Agomelatine—Dizziness—Ifosfamide—hematologic cancer	0.0001	0.000357	CcSEcCtD
Agomelatine—Hepatobiliary disease—Epirubicin—hematologic cancer	9.94e-05	0.000355	CcSEcCtD
Agomelatine—Weight increased—Doxorubicin—hematologic cancer	9.92e-05	0.000354	CcSEcCtD
Agomelatine—Pruritus—Gemcitabine—hematologic cancer	9.91e-05	0.000354	CcSEcCtD
Agomelatine—Vision blurred—Prednisone—hematologic cancer	9.89e-05	0.000353	CcSEcCtD
Agomelatine—Nausea—Thiotepa—hematologic cancer	9.89e-05	0.000353	CcSEcCtD
Agomelatine—Weight decreased—Doxorubicin—hematologic cancer	9.87e-05	0.000352	CcSEcCtD
Agomelatine—Diarrhoea—Irinotecan—hematologic cancer	9.83e-05	0.000351	CcSEcCtD
Agomelatine—Diarrhoea—Mitoxantrone—hematologic cancer	9.83e-05	0.000351	CcSEcCtD
Agomelatine—Vomiting—Carmustine—hematologic cancer	9.83e-05	0.000351	CcSEcCtD
Agomelatine—Insomnia—Triamcinolone—hematologic cancer	9.81e-05	0.00035	CcSEcCtD
Agomelatine—Gastrointestinal pain—Etoposide—hematologic cancer	9.78e-05	0.000349	CcSEcCtD
Agomelatine—Infection—Dexamethasone—hematologic cancer	9.77e-05	0.000349	CcSEcCtD
Agomelatine—Infection—Betamethasone—hematologic cancer	9.77e-05	0.000349	CcSEcCtD
Agomelatine—Dizziness—Vincristine—hematologic cancer	9.76e-05	0.000348	CcSEcCtD
Agomelatine—Vomiting—Alitretinoin—hematologic cancer	9.74e-05	0.000348	CcSEcCtD
Agomelatine—Paraesthesia—Triamcinolone—hematologic cancer	9.74e-05	0.000348	CcSEcCtD
Agomelatine—Infestation—Doxorubicin—hematologic cancer	9.72e-05	0.000347	CcSEcCtD
Agomelatine—Infestation NOS—Doxorubicin—hematologic cancer	9.72e-05	0.000347	CcSEcCtD
Agomelatine—Headache—Carmustine—hematologic cancer	9.69e-05	0.000346	CcSEcCtD
Agomelatine—Nervous system disorder—Betamethasone—hematologic cancer	9.65e-05	0.000345	CcSEcCtD
Agomelatine—Nervous system disorder—Dexamethasone—hematologic cancer	9.65e-05	0.000345	CcSEcCtD
Agomelatine—Agitation—Prednisone—hematologic cancer	9.65e-05	0.000344	CcSEcCtD
Agomelatine—Vomiting—Ifosfamide—hematologic cancer	9.62e-05	0.000344	CcSEcCtD
Agomelatine—Headache—Alitretinoin—hematologic cancer	9.59e-05	0.000343	CcSEcCtD
Agomelatine—Angioedema—Prednisone—hematologic cancer	9.59e-05	0.000343	CcSEcCtD
Agomelatine—Diarrhoea—Gemcitabine—hematologic cancer	9.58e-05	0.000342	CcSEcCtD
Agomelatine—Nausea—Thalidomide—hematologic cancer	9.56e-05	0.000341	CcSEcCtD
Agomelatine—Dyspepsia—Triamcinolone—hematologic cancer	9.55e-05	0.000341	CcSEcCtD
Agomelatine—Hyperhidrosis—Betamethasone—hematologic cancer	9.51e-05	0.00034	CcSEcCtD
Agomelatine—Hyperhidrosis—Dexamethasone—hematologic cancer	9.51e-05	0.00034	CcSEcCtD
Agomelatine—Dizziness—Irinotecan—hematologic cancer	9.5e-05	0.000339	CcSEcCtD
Agomelatine—Urticaria—Etoposide—hematologic cancer	9.5e-05	0.000339	CcSEcCtD
Agomelatine—Jaundice—Doxorubicin—hematologic cancer	9.48e-05	0.000338	CcSEcCtD
Agomelatine—Abdominal pain—Etoposide—hematologic cancer	9.45e-05	0.000337	CcSEcCtD
Agomelatine—Vertigo—Prednisone—hematologic cancer	9.43e-05	0.000337	CcSEcCtD
Agomelatine—Hepatitis—Epirubicin—hematologic cancer	9.43e-05	0.000337	CcSEcCtD
Agomelatine—Eye disorder—Methotrexate—hematologic cancer	9.42e-05	0.000336	CcSEcCtD
Agomelatine—Tinnitus—Methotrexate—hematologic cancer	9.4e-05	0.000336	CcSEcCtD
Agomelatine—Vomiting—Vincristine—hematologic cancer	9.38e-05	0.000335	CcSEcCtD
Agomelatine—Urticaria—Prednisolone—hematologic cancer	9.37e-05	0.000334	CcSEcCtD
Agomelatine—Asthenia—Cisplatin—hematologic cancer	9.36e-05	0.000334	CcSEcCtD
Agomelatine—Fatigue—Triamcinolone—hematologic cancer	9.35e-05	0.000334	CcSEcCtD
Agomelatine—Connective tissue disorder—Epirubicin—hematologic cancer	9.27e-05	0.000331	CcSEcCtD
Agomelatine—Headache—Vincristine—hematologic cancer	9.25e-05	0.00033	CcSEcCtD
Agomelatine—Hepatobiliary disease—Doxorubicin—hematologic cancer	9.2e-05	0.000328	CcSEcCtD
Agomelatine—Nausea—Carmustine—hematologic cancer	9.18e-05	0.000328	CcSEcCtD
Agomelatine—Vomiting—Irinotecan—hematologic cancer	9.14e-05	0.000326	CcSEcCtD
Agomelatine—Vomiting—Mitoxantrone—hematologic cancer	9.14e-05	0.000326	CcSEcCtD
Agomelatine—Nausea—Alitretinoin—hematologic cancer	9.1e-05	0.000325	CcSEcCtD
Agomelatine—Headache—Mitoxantrone—hematologic cancer	9e-05	0.000321	CcSEcCtD
Agomelatine—Headache—Irinotecan—hematologic cancer	9e-05	0.000321	CcSEcCtD
Agomelatine—Nausea—Ifosfamide—hematologic cancer	8.99e-05	0.000321	CcSEcCtD
Agomelatine—Diarrhoea—Cisplatin—hematologic cancer	8.93e-05	0.000319	CcSEcCtD
Agomelatine—Anxiety—Prednisone—hematologic cancer	8.91e-05	0.000318	CcSEcCtD
Agomelatine—Vomiting—Gemcitabine—hematologic cancer	8.9e-05	0.000318	CcSEcCtD
Agomelatine—Insomnia—Betamethasone—hematologic cancer	8.9e-05	0.000318	CcSEcCtD
Agomelatine—Insomnia—Dexamethasone—hematologic cancer	8.9e-05	0.000318	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	8.88e-05	0.000317	CcSEcCtD
Agomelatine—Paraesthesia—Dexamethasone—hematologic cancer	8.84e-05	0.000315	CcSEcCtD
Agomelatine—Paraesthesia—Betamethasone—hematologic cancer	8.84e-05	0.000315	CcSEcCtD
Agomelatine—Mental disorder—Methotrexate—hematologic cancer	8.83e-05	0.000315	CcSEcCtD
Agomelatine—Eye disorder—Epirubicin—hematologic cancer	8.82e-05	0.000315	CcSEcCtD
Agomelatine—Tinnitus—Epirubicin—hematologic cancer	8.79e-05	0.000314	CcSEcCtD
Agomelatine—Headache—Gemcitabine—hematologic cancer	8.77e-05	0.000313	CcSEcCtD
Agomelatine—Nausea—Vincristine—hematologic cancer	8.77e-05	0.000313	CcSEcCtD
Agomelatine—Hepatitis—Doxorubicin—hematologic cancer	8.73e-05	0.000312	CcSEcCtD
Agomelatine—Dyspepsia—Dexamethasone—hematologic cancer	8.66e-05	0.000309	CcSEcCtD
Agomelatine—Dyspepsia—Betamethasone—hematologic cancer	8.66e-05	0.000309	CcSEcCtD
Agomelatine—Urticaria—Triamcinolone—hematologic cancer	8.61e-05	0.000308	CcSEcCtD
Agomelatine—Asthenia—Etoposide—hematologic cancer	8.58e-05	0.000306	CcSEcCtD
Agomelatine—Connective tissue disorder—Doxorubicin—hematologic cancer	8.58e-05	0.000306	CcSEcCtD
Agomelatine—Nausea—Mitoxantrone—hematologic cancer	8.54e-05	0.000305	CcSEcCtD
Agomelatine—Nausea—Irinotecan—hematologic cancer	8.54e-05	0.000305	CcSEcCtD
Agomelatine—Infection—Prednisone—hematologic cancer	8.51e-05	0.000304	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Betamethasone—hematologic cancer	8.49e-05	0.000303	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Dexamethasone—hematologic cancer	8.49e-05	0.000303	CcSEcCtD
Agomelatine—Back pain—Methotrexate—hematologic cancer	8.49e-05	0.000303	CcSEcCtD
Agomelatine—Fatigue—Betamethasone—hematologic cancer	8.48e-05	0.000303	CcSEcCtD
Agomelatine—Fatigue—Dexamethasone—hematologic cancer	8.48e-05	0.000303	CcSEcCtD
Agomelatine—Pruritus—Etoposide—hematologic cancer	8.46e-05	0.000302	CcSEcCtD
Agomelatine—Nervous system disorder—Prednisone—hematologic cancer	8.4e-05	0.0003	CcSEcCtD
Agomelatine—Skin disorder—Prednisone—hematologic cancer	8.32e-05	0.000297	CcSEcCtD
Agomelatine—Nausea—Gemcitabine—hematologic cancer	8.32e-05	0.000297	CcSEcCtD
Agomelatine—Vomiting—Cisplatin—hematologic cancer	8.3e-05	0.000296	CcSEcCtD
Agomelatine—Hyperhidrosis—Prednisone—hematologic cancer	8.28e-05	0.000296	CcSEcCtD
Agomelatine—Vision blurred—Methotrexate—hematologic cancer	8.27e-05	0.000295	CcSEcCtD
Agomelatine—Mental disorder—Epirubicin—hematologic cancer	8.26e-05	0.000295	CcSEcCtD
Agomelatine—Diarrhoea—Etoposide—hematologic cancer	8.18e-05	0.000292	CcSEcCtD
Agomelatine—Eye disorder—Doxorubicin—hematologic cancer	8.16e-05	0.000291	CcSEcCtD
Agomelatine—Tinnitus—Doxorubicin—hematologic cancer	8.14e-05	0.000291	CcSEcCtD
Agomelatine—Gastrointestinal pain—Dexamethasone—hematologic cancer	8.05e-05	0.000287	CcSEcCtD
Agomelatine—Gastrointestinal pain—Betamethasone—hematologic cancer	8.05e-05	0.000287	CcSEcCtD
Agomelatine—Back pain—Epirubicin—hematologic cancer	7.94e-05	0.000284	CcSEcCtD
Agomelatine—Dizziness—Etoposide—hematologic cancer	7.91e-05	0.000282	CcSEcCtD
Agomelatine—Vertigo—Methotrexate—hematologic cancer	7.88e-05	0.000281	CcSEcCtD
Agomelatine—Urticaria—Dexamethasone—hematologic cancer	7.82e-05	0.000279	CcSEcCtD
Agomelatine—Urticaria—Betamethasone—hematologic cancer	7.82e-05	0.000279	CcSEcCtD
Agomelatine—Dizziness—Prednisolone—hematologic cancer	7.8e-05	0.000278	CcSEcCtD
Agomelatine—Asthenia—Triamcinolone—hematologic cancer	7.78e-05	0.000278	CcSEcCtD
Agomelatine—Abdominal pain—Betamethasone—hematologic cancer	7.78e-05	0.000278	CcSEcCtD
Agomelatine—Abdominal pain—Dexamethasone—hematologic cancer	7.78e-05	0.000278	CcSEcCtD
Agomelatine—Nausea—Cisplatin—hematologic cancer	7.75e-05	0.000277	CcSEcCtD
Agomelatine—Insomnia—Prednisone—hematologic cancer	7.75e-05	0.000277	CcSEcCtD
Agomelatine—Vision blurred—Epirubicin—hematologic cancer	7.74e-05	0.000276	CcSEcCtD
Agomelatine—Paraesthesia—Prednisone—hematologic cancer	7.69e-05	0.000275	CcSEcCtD
Agomelatine—Pruritus—Triamcinolone—hematologic cancer	7.67e-05	0.000274	CcSEcCtD
Agomelatine—Mental disorder—Doxorubicin—hematologic cancer	7.65e-05	0.000273	CcSEcCtD
Agomelatine—Vomiting—Etoposide—hematologic cancer	7.6e-05	0.000271	CcSEcCtD
Agomelatine—Agitation—Epirubicin—hematologic cancer	7.55e-05	0.000269	CcSEcCtD
Agomelatine—Dyspepsia—Prednisone—hematologic cancer	7.54e-05	0.000269	CcSEcCtD
Agomelatine—Headache—Etoposide—hematologic cancer	7.49e-05	0.000267	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	7.42e-05	0.000265	CcSEcCtD
Agomelatine—Fatigue—Prednisone—hematologic cancer	7.39e-05	0.000264	CcSEcCtD
Agomelatine—Headache—Prednisolone—hematologic cancer	7.39e-05	0.000264	CcSEcCtD
Agomelatine—Vertigo—Epirubicin—hematologic cancer	7.38e-05	0.000263	CcSEcCtD
Agomelatine—Back pain—Doxorubicin—hematologic cancer	7.35e-05	0.000262	CcSEcCtD
Agomelatine—Constipation—Prednisone—hematologic cancer	7.33e-05	0.000262	CcSEcCtD
Agomelatine—Dizziness—Triamcinolone—hematologic cancer	7.17e-05	0.000256	CcSEcCtD
Agomelatine—Vision blurred—Doxorubicin—hematologic cancer	7.16e-05	0.000256	CcSEcCtD
Agomelatine—Infection—Methotrexate—hematologic cancer	7.11e-05	0.000254	CcSEcCtD
Agomelatine—Nausea—Etoposide—hematologic cancer	7.1e-05	0.000254	CcSEcCtD
Agomelatine—Asthenia—Dexamethasone—hematologic cancer	7.06e-05	0.000252	CcSEcCtD
Agomelatine—Asthenia—Betamethasone—hematologic cancer	7.06e-05	0.000252	CcSEcCtD
Agomelatine—Nervous system disorder—Methotrexate—hematologic cancer	7.02e-05	0.000251	CcSEcCtD
Agomelatine—Gastrointestinal pain—Prednisone—hematologic cancer	7.01e-05	0.00025	CcSEcCtD
Agomelatine—Nausea—Prednisolone—hematologic cancer	7e-05	0.00025	CcSEcCtD
Agomelatine—Agitation—Doxorubicin—hematologic cancer	6.98e-05	0.000249	CcSEcCtD
Agomelatine—Anxiety—Epirubicin—hematologic cancer	6.97e-05	0.000249	CcSEcCtD
Agomelatine—Pruritus—Dexamethasone—hematologic cancer	6.96e-05	0.000249	CcSEcCtD
Agomelatine—Pruritus—Betamethasone—hematologic cancer	6.96e-05	0.000249	CcSEcCtD
Agomelatine—Skin disorder—Methotrexate—hematologic cancer	6.96e-05	0.000248	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	6.94e-05	0.000248	CcSEcCtD
Agomelatine—Hyperhidrosis—Methotrexate—hematologic cancer	6.92e-05	0.000247	CcSEcCtD
Agomelatine—Vomiting—Triamcinolone—hematologic cancer	6.89e-05	0.000246	CcSEcCtD
Agomelatine—Dry mouth—Epirubicin—hematologic cancer	6.84e-05	0.000244	CcSEcCtD
Agomelatine—Vertigo—Doxorubicin—hematologic cancer	6.83e-05	0.000244	CcSEcCtD
Agomelatine—Urticaria—Prednisone—hematologic cancer	6.81e-05	0.000243	CcSEcCtD
Agomelatine—Headache—Triamcinolone—hematologic cancer	6.79e-05	0.000243	CcSEcCtD
Agomelatine—Abdominal pain—Prednisone—hematologic cancer	6.77e-05	0.000242	CcSEcCtD
Agomelatine—Diarrhoea—Dexamethasone—hematologic cancer	6.73e-05	0.00024	CcSEcCtD
Agomelatine—Diarrhoea—Betamethasone—hematologic cancer	6.73e-05	0.00024	CcSEcCtD
Agomelatine—Infection—Epirubicin—hematologic cancer	6.66e-05	0.000238	CcSEcCtD
Agomelatine—Nervous system disorder—Epirubicin—hematologic cancer	6.57e-05	0.000235	CcSEcCtD
Agomelatine—Skin disorder—Epirubicin—hematologic cancer	6.51e-05	0.000232	CcSEcCtD
Agomelatine—Dizziness—Dexamethasone—hematologic cancer	6.51e-05	0.000232	CcSEcCtD
Agomelatine—Dizziness—Betamethasone—hematologic cancer	6.51e-05	0.000232	CcSEcCtD
Agomelatine—Hyperhidrosis—Epirubicin—hematologic cancer	6.48e-05	0.000231	CcSEcCtD
Agomelatine—Insomnia—Methotrexate—hematologic cancer	6.48e-05	0.000231	CcSEcCtD
Agomelatine—Anxiety—Doxorubicin—hematologic cancer	6.45e-05	0.00023	CcSEcCtD
Agomelatine—Nausea—Triamcinolone—hematologic cancer	6.44e-05	0.00023	CcSEcCtD
Agomelatine—Paraesthesia—Methotrexate—hematologic cancer	6.43e-05	0.00023	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	6.42e-05	0.000229	CcSEcCtD
Agomelatine—Somnolence—Methotrexate—hematologic cancer	6.37e-05	0.000227	CcSEcCtD
Agomelatine—Dry mouth—Doxorubicin—hematologic cancer	6.33e-05	0.000226	CcSEcCtD
Agomelatine—Dyspepsia—Methotrexate—hematologic cancer	6.3e-05	0.000225	CcSEcCtD
Agomelatine—Vomiting—Dexamethasone—hematologic cancer	6.26e-05	0.000223	CcSEcCtD
Agomelatine—Vomiting—Betamethasone—hematologic cancer	6.26e-05	0.000223	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Methotrexate—hematologic cancer	6.18e-05	0.000221	CcSEcCtD
Agomelatine—Fatigue—Methotrexate—hematologic cancer	6.17e-05	0.00022	CcSEcCtD
Agomelatine—Headache—Betamethasone—hematologic cancer	6.16e-05	0.00022	CcSEcCtD
Agomelatine—Headache—Dexamethasone—hematologic cancer	6.16e-05	0.00022	CcSEcCtD
Agomelatine—Infection—Doxorubicin—hematologic cancer	6.16e-05	0.00022	CcSEcCtD
Agomelatine—Asthenia—Prednisone—hematologic cancer	6.15e-05	0.00022	CcSEcCtD
Agomelatine—Nervous system disorder—Doxorubicin—hematologic cancer	6.08e-05	0.000217	CcSEcCtD
Agomelatine—Pruritus—Prednisone—hematologic cancer	6.06e-05	0.000216	CcSEcCtD
Agomelatine—Insomnia—Epirubicin—hematologic cancer	6.06e-05	0.000216	CcSEcCtD
Agomelatine—Skin disorder—Doxorubicin—hematologic cancer	6.02e-05	0.000215	CcSEcCtD
Agomelatine—Paraesthesia—Epirubicin—hematologic cancer	6.02e-05	0.000215	CcSEcCtD
Agomelatine—Hyperhidrosis—Doxorubicin—hematologic cancer	5.99e-05	0.000214	CcSEcCtD
Agomelatine—Somnolence—Epirubicin—hematologic cancer	5.96e-05	0.000213	CcSEcCtD
Agomelatine—Dyspepsia—Epirubicin—hematologic cancer	5.9e-05	0.000211	CcSEcCtD
Agomelatine—Diarrhoea—Prednisone—hematologic cancer	5.86e-05	0.000209	CcSEcCtD
Agomelatine—Gastrointestinal pain—Methotrexate—hematologic cancer	5.86e-05	0.000209	CcSEcCtD
Agomelatine—Nausea—Dexamethasone—hematologic cancer	5.84e-05	0.000209	CcSEcCtD
Agomelatine—Nausea—Betamethasone—hematologic cancer	5.84e-05	0.000209	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Epirubicin—hematologic cancer	5.79e-05	0.000207	CcSEcCtD
Agomelatine—Fatigue—Epirubicin—hematologic cancer	5.78e-05	0.000206	CcSEcCtD
Agomelatine—Constipation—Epirubicin—hematologic cancer	5.73e-05	0.000205	CcSEcCtD
Agomelatine—Urticaria—Methotrexate—hematologic cancer	5.69e-05	0.000203	CcSEcCtD
Agomelatine—Dizziness—Prednisone—hematologic cancer	5.67e-05	0.000202	CcSEcCtD
Agomelatine—Abdominal pain—Methotrexate—hematologic cancer	5.66e-05	0.000202	CcSEcCtD
Agomelatine—Insomnia—Doxorubicin—hematologic cancer	5.61e-05	0.0002	CcSEcCtD
Agomelatine—Paraesthesia—Doxorubicin—hematologic cancer	5.57e-05	0.000199	CcSEcCtD
Agomelatine—Somnolence—Doxorubicin—hematologic cancer	5.51e-05	0.000197	CcSEcCtD
Agomelatine—Gastrointestinal pain—Epirubicin—hematologic cancer	5.48e-05	0.000196	CcSEcCtD
Agomelatine—Dyspepsia—Doxorubicin—hematologic cancer	5.46e-05	0.000195	CcSEcCtD
Agomelatine—Vomiting—Prednisone—hematologic cancer	5.45e-05	0.000195	CcSEcCtD
Agomelatine—Headache—Prednisone—hematologic cancer	5.37e-05	0.000192	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Doxorubicin—hematologic cancer	5.35e-05	0.000191	CcSEcCtD
Agomelatine—Fatigue—Doxorubicin—hematologic cancer	5.35e-05	0.000191	CcSEcCtD
Agomelatine—Urticaria—Epirubicin—hematologic cancer	5.32e-05	0.00019	CcSEcCtD
Agomelatine—Constipation—Doxorubicin—hematologic cancer	5.3e-05	0.000189	CcSEcCtD
Agomelatine—Abdominal pain—Epirubicin—hematologic cancer	5.3e-05	0.000189	CcSEcCtD
Agomelatine—Asthenia—Methotrexate—hematologic cancer	5.14e-05	0.000183	CcSEcCtD
Agomelatine—Nausea—Prednisone—hematologic cancer	5.09e-05	0.000182	CcSEcCtD
Agomelatine—Gastrointestinal pain—Doxorubicin—hematologic cancer	5.07e-05	0.000181	CcSEcCtD
Agomelatine—Pruritus—Methotrexate—hematologic cancer	5.07e-05	0.000181	CcSEcCtD
Agomelatine—Urticaria—Doxorubicin—hematologic cancer	4.93e-05	0.000176	CcSEcCtD
Agomelatine—Abdominal pain—Doxorubicin—hematologic cancer	4.9e-05	0.000175	CcSEcCtD
Agomelatine—Diarrhoea—Methotrexate—hematologic cancer	4.9e-05	0.000175	CcSEcCtD
Agomelatine—Asthenia—Epirubicin—hematologic cancer	4.81e-05	0.000172	CcSEcCtD
Agomelatine—Pruritus—Epirubicin—hematologic cancer	4.74e-05	0.000169	CcSEcCtD
Agomelatine—Dizziness—Methotrexate—hematologic cancer	4.74e-05	0.000169	CcSEcCtD
Agomelatine—Diarrhoea—Epirubicin—hematologic cancer	4.59e-05	0.000164	CcSEcCtD
Agomelatine—Vomiting—Methotrexate—hematologic cancer	4.55e-05	0.000163	CcSEcCtD
Agomelatine—Headache—Methotrexate—hematologic cancer	4.49e-05	0.00016	CcSEcCtD
Agomelatine—Asthenia—Doxorubicin—hematologic cancer	4.45e-05	0.000159	CcSEcCtD
Agomelatine—Dizziness—Epirubicin—hematologic cancer	4.43e-05	0.000158	CcSEcCtD
Agomelatine—Pruritus—Doxorubicin—hematologic cancer	4.39e-05	0.000157	CcSEcCtD
Agomelatine—Vomiting—Epirubicin—hematologic cancer	4.26e-05	0.000152	CcSEcCtD
Agomelatine—Nausea—Methotrexate—hematologic cancer	4.25e-05	0.000152	CcSEcCtD
Agomelatine—Diarrhoea—Doxorubicin—hematologic cancer	4.24e-05	0.000151	CcSEcCtD
Agomelatine—Headache—Epirubicin—hematologic cancer	4.2e-05	0.00015	CcSEcCtD
Agomelatine—Dizziness—Doxorubicin—hematologic cancer	4.1e-05	0.000146	CcSEcCtD
Agomelatine—Nausea—Epirubicin—hematologic cancer	3.98e-05	0.000142	CcSEcCtD
Agomelatine—Vomiting—Doxorubicin—hematologic cancer	3.94e-05	0.000141	CcSEcCtD
Agomelatine—Headache—Doxorubicin—hematologic cancer	3.88e-05	0.000139	CcSEcCtD
Agomelatine—Nausea—Doxorubicin—hematologic cancer	3.68e-05	0.000132	CcSEcCtD
Agomelatine—HTR2B—GPCR downstream signaling—IL2—hematologic cancer	1.2e-05	9.13e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PDGFRB—hematologic cancer	1.2e-05	9.12e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—CREB1—hematologic cancer	1.19e-05	9.05e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—PIK3CB—hematologic cancer	1.18e-05	9.03e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PDGFRA—hematologic cancer	1.18e-05	8.97e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—JAK1—hematologic cancer	1.17e-05	8.94e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PRKCG—hematologic cancer	1.17e-05	8.94e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—STAT1—hematologic cancer	1.17e-05	8.94e-05	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—IL6—hematologic cancer	1.17e-05	8.92e-05	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—IL6—hematologic cancer	1.17e-05	8.92e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—hematologic cancer	1.16e-05	8.85e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—CCL2—hematologic cancer	1.16e-05	8.85e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—ARNTL—hematologic cancer	1.16e-05	8.83e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—IL6R—hematologic cancer	1.16e-05	8.82e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—UGT1A1—hematologic cancer	1.15e-05	8.78e-05	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—PIK3R1—hematologic cancer	1.14e-05	8.69e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CA9—hematologic cancer	1.13e-05	8.59e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—ACP5—hematologic cancer	1.13e-05	8.59e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CRABP1—hematologic cancer	1.12e-05	8.54e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—SLC22A1—hematologic cancer	1.12e-05	8.54e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—NCOR2—hematologic cancer	1.11e-05	8.48e-05	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—JAK2—hematologic cancer	1.11e-05	8.44e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—MAP2K1—hematologic cancer	1.1e-05	8.41e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—GRB2—hematologic cancer	1.1e-05	8.37e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—PIK3CD—hematologic cancer	1.1e-05	8.35e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—IL2RA—hematologic cancer	1.1e-05	8.35e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PDGFA—hematologic cancer	1.1e-05	8.35e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—ALOX5—hematologic cancer	1.09e-05	8.33e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—IL2—hematologic cancer	1.09e-05	8.29e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—TERT—hematologic cancer	1.08e-05	8.26e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—KITLG—hematologic cancer	1.08e-05	8.23e-05	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—AKT1—hematologic cancer	1.08e-05	8.23e-05	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—AKT1—hematologic cancer	1.08e-05	8.23e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—IDH1—hematologic cancer	1.06e-05	8.07e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—NUP98—hematologic cancer	1.06e-05	8.06e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PDGFB—hematologic cancer	1.06e-05	8.06e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—STAT5A—hematologic cancer	1.06e-05	8.04e-05	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—PIK3CB—hematologic cancer	1.05e-05	8.02e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—ABCC3—hematologic cancer	1.05e-05	7.98e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GSTO1—hematologic cancer	1.05e-05	7.98e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—TXN—hematologic cancer	1.05e-05	7.98e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CDKN2B—hematologic cancer	1.05e-05	7.97e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—PIK3R1—hematologic cancer	1.04e-05	7.89e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—TSC2—hematologic cancer	1.03e-05	7.88e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—ADCY7—hematologic cancer	1.03e-05	7.83e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—NCOA3—hematologic cancer	1.03e-05	7.83e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—SPHK1—hematologic cancer	1.03e-05	7.81e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—NUP214—hematologic cancer	1.02e-05	7.77e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CD86—hematologic cancer	1.01e-05	7.71e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	1.01e-05	7.69e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—JAK2—hematologic cancer	1.01e-05	7.67e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—MTR—hematologic cancer	9.99e-06	7.62e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—ABCG2—hematologic cancer	9.99e-06	7.62e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—HES1—hematologic cancer	9.98e-06	7.6e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—FGFR3—hematologic cancer	9.95e-06	7.58e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—NCOR1—hematologic cancer	9.92e-06	7.56e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—UGT1A1—hematologic cancer	9.85e-06	7.51e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MAPK14—hematologic cancer	9.85e-06	7.5e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CSF2—hematologic cancer	9.81e-06	7.48e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—FGF1—hematologic cancer	9.81e-06	7.48e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—ENO2—hematologic cancer	9.8e-06	7.47e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—FOXO1—hematologic cancer	9.67e-06	7.37e-05	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—IL2—hematologic cancer	9.66e-06	7.36e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—ESR1—hematologic cancer	9.66e-06	7.36e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PDGFRB—hematologic cancer	9.65e-06	7.35e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—SLC22A1—hematologic cancer	9.58e-06	7.3e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CRABP1—hematologic cancer	9.58e-06	7.3e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—PIK3CB—hematologic cancer	9.56e-06	7.28e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—FN1—hematologic cancer	9.54e-06	7.27e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—GSTT1—hematologic cancer	9.51e-06	7.24e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PDGFRA—hematologic cancer	9.5e-06	7.24e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PRKCG—hematologic cancer	9.47e-06	7.22e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—JAK1—hematologic cancer	9.47e-06	7.22e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—BAD—hematologic cancer	9.43e-06	7.18e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—NFKBIA—hematologic cancer	9.43e-06	7.18e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	9.36e-06	7.13e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—ALOX5—hematologic cancer	9.34e-06	7.12e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—NOTCH1—hematologic cancer	9.34e-06	7.12e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—SDC1—hematologic cancer	9.29e-06	7.08e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CD80—hematologic cancer	9.15e-06	6.97e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PIK3CG—hematologic cancer	9.13e-06	6.96e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—KIT—hematologic cancer	9.13e-06	6.96e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—NRAS—hematologic cancer	9.13e-06	6.96e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—NUP98—hematologic cancer	9.04e-06	6.89e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PTPN11—hematologic cancer	8.97e-06	6.84e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	8.88e-06	6.76e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—IL2RA—hematologic cancer	8.84e-06	6.74e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—ADCY7—hematologic cancer	8.78e-06	6.69e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—NCOA3—hematologic cancer	8.78e-06	6.69e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—IL2—hematologic cancer	8.78e-06	6.69e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	8.76e-06	6.68e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—MAPK3—hematologic cancer	8.74e-06	6.66e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—TERT—hematologic cancer	8.74e-06	6.66e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—NUP214—hematologic cancer	8.72e-06	6.64e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CREB1—hematologic cancer	8.69e-06	6.62e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	8.63e-06	6.57e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—BRAF—hematologic cancer	8.58e-06	6.54e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—ABCG2—hematologic cancer	8.54e-06	6.51e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—MTR—hematologic cancer	8.54e-06	6.51e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PDGFB—hematologic cancer	8.53e-06	6.5e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CCL2—hematologic cancer	8.5e-06	6.48e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—IL6R—hematologic cancer	8.48e-06	6.46e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CREBBP—hematologic cancer	8.47e-06	6.45e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	8.38e-06	6.39e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—ENO2—hematologic cancer	8.38e-06	6.38e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—TSC2—hematologic cancer	8.34e-06	6.36e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GSTT1—hematologic cancer	8.12e-06	6.19e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MAP2K1—hematologic cancer	8.08e-06	6.16e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PIK3CD—hematologic cancer	8.03e-06	6.12e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—FGFR3—hematologic cancer	8.02e-06	6.11e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	8e-06	6.1e-05	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—PIK3CA—hematologic cancer	7.95e-06	6.06e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MAPK14—hematologic cancer	7.94e-06	6.05e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—SDC1—hematologic cancer	7.94e-06	6.05e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CD44—hematologic cancer	7.9e-06	6.02e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—NQO1—hematologic cancer	7.9e-06	6.02e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—KRAS—hematologic cancer	7.86e-06	5.99e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—ESR1—hematologic cancer	7.79e-06	5.94e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	7.74e-06	5.9e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—FN1—hematologic cancer	7.7e-06	5.87e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—FGF2—hematologic cancer	7.69e-06	5.86e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—BAD—hematologic cancer	7.61e-06	5.8e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—NFKBIA—hematologic cancer	7.61e-06	5.8e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	7.58e-06	5.78e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PIK3R1—hematologic cancer	7.58e-06	5.78e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—NOTCH1—hematologic cancer	7.53e-06	5.74e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	7.49e-06	5.71e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CYCS—hematologic cancer	7.48e-06	5.7e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—HSP90AA1—hematologic cancer	7.43e-06	5.66e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CD80—hematologic cancer	7.38e-06	5.62e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—JAK2—hematologic cancer	7.37e-06	5.61e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PIK3CG—hematologic cancer	7.37e-06	5.61e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—KIT—hematologic cancer	7.37e-06	5.61e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—NRAS—hematologic cancer	7.37e-06	5.61e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PTPN11—hematologic cancer	7.24e-06	5.52e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—PIK3CA—hematologic cancer	7.22e-06	5.5e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MDM2—hematologic cancer	7.19e-06	5.48e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	7.16e-06	5.46e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—MAPK3—hematologic cancer	7.05e-06	5.38e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CREB1—hematologic cancer	7.01e-06	5.34e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MTOR—hematologic cancer	7e-06	5.33e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PIK3CB—hematologic cancer	7e-06	5.33e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—BRAF—hematologic cancer	6.92e-06	5.28e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CCL2—hematologic cancer	6.86e-06	5.23e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—IL6R—hematologic cancer	6.84e-06	5.21e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CREBBP—hematologic cancer	6.83e-06	5.2e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—NQO1—hematologic cancer	6.75e-06	5.14e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CD44—hematologic cancer	6.75e-06	5.14e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	6.68e-06	5.09e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—HRAS—hematologic cancer	6.68e-06	5.09e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	6.61e-06	5.04e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—GSTP1—hematologic cancer	6.59e-06	5.02e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CDKN1B—hematologic cancer	6.57e-06	5e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MAP2K1—hematologic cancer	6.52e-06	4.97e-05	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—AKT1—hematologic cancer	6.5e-06	4.95e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PIK3CD—hematologic cancer	6.48e-06	4.94e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CASP3—hematologic cancer	6.44e-06	4.9e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—IL2—hematologic cancer	6.43e-06	4.9e-05	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—PIK3CA—hematologic cancer	6.41e-06	4.89e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—IL6—hematologic cancer	6.39e-06	4.87e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CYCS—hematologic cancer	6.39e-06	4.87e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	6.37e-06	4.86e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—HSP90AA1—hematologic cancer	6.35e-06	4.84e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—KRAS—hematologic cancer	6.34e-06	4.83e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CCND1—hematologic cancer	6.26e-06	4.77e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—JUN—hematologic cancer	6.25e-06	4.76e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—ABCB1—hematologic cancer	6.24e-06	4.75e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—FGF2—hematologic cancer	6.2e-06	4.73e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PIK3R1—hematologic cancer	6.12e-06	4.66e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CDKN1A—hematologic cancer	6.06e-06	4.62e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—GSTM1—hematologic cancer	6.06e-06	4.61e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—NCOR1—hematologic cancer	6.06e-06	4.61e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PTEN—hematologic cancer	6.05e-06	4.61e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—JAK2—hematologic cancer	5.94e-06	4.53e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MAPK8—hematologic cancer	5.91e-06	4.51e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—AKT1—hematologic cancer	5.9e-06	4.49e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—PIK3CA—hematologic cancer	5.82e-06	4.44e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MDM2—hematologic cancer	5.8e-06	4.42e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—EP300—hematologic cancer	5.77e-06	4.39e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	5.71e-06	4.35e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PIK3CB—hematologic cancer	5.64e-06	4.3e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MTOR—hematologic cancer	5.64e-06	4.3e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GSTP1—hematologic cancer	5.63e-06	4.29e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—SRC—hematologic cancer	5.61e-06	4.27e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—VEGFA—hematologic cancer	5.46e-06	4.16e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	5.45e-06	4.15e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—STAT3—hematologic cancer	5.41e-06	4.12e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—NRAS—hematologic cancer	5.39e-06	4.11e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—HRAS—hematologic cancer	5.39e-06	4.11e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—MTHFR—hematologic cancer	5.35e-06	4.08e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—ABCB1—hematologic cancer	5.33e-06	4.06e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CDKN1B—hematologic cancer	5.3e-06	4.04e-05	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—AKT1—hematologic cancer	5.24e-06	3.99e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CASP3—hematologic cancer	5.19e-06	3.96e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—IL2—hematologic cancer	5.18e-06	3.95e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—NCOR1—hematologic cancer	5.17e-06	3.94e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GSTM1—hematologic cancer	5.17e-06	3.94e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MAPK3—hematologic cancer	5.17e-06	3.94e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—IL6—hematologic cancer	5.16e-06	3.93e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CCND1—hematologic cancer	5.05e-06	3.85e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—JUN—hematologic cancer	5.04e-06	3.84e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MYC—hematologic cancer	5.02e-06	3.83e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—TGFB1—hematologic cancer	5.01e-06	3.82e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CDKN1A—hematologic cancer	4.89e-06	3.73e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PTEN—hematologic cancer	4.88e-06	3.72e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MAPK8—hematologic cancer	4.77e-06	3.64e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—AKT1—hematologic cancer	4.76e-06	3.63e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	4.72e-06	3.59e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—EP300—hematologic cancer	4.65e-06	3.54e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—KRAS—hematologic cancer	4.64e-06	3.54e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—MTHFR—hematologic cancer	4.57e-06	3.48e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—SRC—hematologic cancer	4.52e-06	3.45e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PIK3CG—hematologic cancer	4.5e-06	3.43e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—VEGFA—hematologic cancer	4.41e-06	3.36e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—STAT3—hematologic cancer	4.36e-06	3.32e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—NRAS—hematologic cancer	4.35e-06	3.32e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PIK3CA—hematologic cancer	4.27e-06	3.25e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CREBBP—hematologic cancer	4.17e-06	3.18e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MAPK3—hematologic cancer	4.17e-06	3.18e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—TP53—hematologic cancer	4.13e-06	3.14e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MYC—hematologic cancer	4.05e-06	3.09e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—TGFB1—hematologic cancer	4.04e-06	3.08e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	4.03e-06	3.07e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PIK3CD—hematologic cancer	3.95e-06	3.01e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—HRAS—hematologic cancer	3.95e-06	3.01e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—ALB—hematologic cancer	3.9e-06	2.97e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PIK3CG—hematologic cancer	3.84e-06	2.93e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—IL6—hematologic cancer	3.78e-06	2.88e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—KRAS—hematologic cancer	3.75e-06	2.85e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PIK3R1—hematologic cancer	3.73e-06	2.84e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CREBBP—hematologic cancer	3.56e-06	2.71e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—AKT1—hematologic cancer	3.48e-06	2.66e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PIK3CB—hematologic cancer	3.45e-06	2.63e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PIK3CA—hematologic cancer	3.44e-06	2.62e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PIK3CD—hematologic cancer	3.38e-06	2.57e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—ALB—hematologic cancer	3.33e-06	2.54e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—TP53—hematologic cancer	3.33e-06	2.54e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PIK3R1—hematologic cancer	3.19e-06	2.43e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—HRAS—hematologic cancer	3.18e-06	2.43e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—IL6—hematologic cancer	3.05e-06	2.32e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PTEN—hematologic cancer	2.98e-06	2.27e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PIK3CB—hematologic cancer	2.94e-06	2.24e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—EP300—hematologic cancer	2.84e-06	2.16e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—AKT1—hematologic cancer	2.81e-06	2.14e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PTEN—hematologic cancer	2.54e-06	1.94e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—EP300—hematologic cancer	2.43e-06	1.85e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PIK3CA—hematologic cancer	2.1e-06	1.6e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PIK3CA—hematologic cancer	1.79e-06	1.37e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—AKT1—hematologic cancer	1.72e-06	1.31e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—AKT1—hematologic cancer	1.47e-06	1.12e-05	CbGpPWpGaD
